New developments further strengthen Bone Therapeutics’ cell product manufacturing capabilities

Updating on the February 15th post, some exciting new developments have recently occurred that further strengthen Bone Therapeutics’ cell product manufacturing capabilities. Following a successful Series D fundraising round, Bone Therapeutics, alongside the Walloon Region and private investors, has invested in Skeletal Cell Therapy Support S.A (SCTS) to fund the construction of a new state-of-the-art manufacturing facility based in the Gosselies Scientific Park near Brussels, Belgium. This investment will allow it to produce its unique bone cell therapy products for the treatment of bone diseases under GMP conditions and will also provide SCTS customers with state-of-the-art facilities tailored to meet the specific demands of the cell therapy industry.

In March, the company was awarded ‘Tissue Establishment and ‘GMP’ Accreditation for the manufacturing of its allogeneic bone cell therapy product initially being developed for the treatment of non-union fractures. In addition to the allogeneic platform, Bone Therapeutics also has autologous ‘Production Establishment Accreditation’ and manufacturing authorizations that will enable the company to work on its autologous bone cell product.

With the manufacturing process now fully secured Bone Therapeutics will work in collaboration with the LTCG, the accredited Tissue Bank from the CHU Sart-Tilman based in Liège, Belgium and headed up by Prof. Yves Beguin. Upon completion of construction in 2015, Bone Therapeutics will be headquartered at the Gosselies Scientific Park facility.

Additional News: Bone Therapeutics and Erasme University Hospital start first-of-its-kind trial to investigate bone cell therapy in severe treatment-resistant osteoporosis. The Rheumatology Department of Erasme University Hospital (Brussels, Belgium), has initiated a Phase IIa trial with Bone Therapeutics’ first-in-class autologous osteoblastic (bone forming) cell therapy product. This Phase IIa study is a six-month open-label trial enrolling 20 patients with severe osteoporosis who do not respond to anti-osteoporotic treatment. (read more)

For more on this story please visit the previous post from http://win-health.org/bone-therapeutics-completes-a-e7-7-million-series-d-fundraising-round-to-further-advance-ongoing-preob®-phase-iii-clinical-trials/bonetherapeutics.com

Bone Therapeutics S.A.
Rue Adrienne Bolland, 8
6041 Gosselies – Belgium (Europe)
Phone: +32 (0) 2 529 59 90
Fax: +32 (0) 2 529 59 93

Enrico Bastianelli, Chief Executive Officer
info@bonetherapeutics.com
Phone: +32 (0) 2 529 59 90

Communications:

Enrico Bastianelli, Chief Executive Officer
info@bonetherapeutics.com
Phone: +32 (0) 2 529 59 90

Mary-Jane Elliott, Amber Bielecka, Hollie Vile
bonetherapeutics@mcomgroup.com
Tel: +44 (0) 20 7920 2333

Related Articles

Share

About Author

Win-health

(0) Readers Comments

Comments are closed.